Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
2. Cgp 33101
3. Cgp-33101
4. Inovelon
1. 106308-44-5
2. Banzel
3. Inovelon
4. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazole-4-carboxamide
5. Cgp 33101
6. Cgp-33101
7. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4-carboxamide
8. Ruf 331
9. Xilep
10. Ruf-331
11. 1-[(2,6-difluorophenyl)methyl]triazole-4-carboxamide
12. E-2080
13. E2080
14. E 2080
15. Wfw942pr79
16. 1h-1,2,3-triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]-
17. Ncgc00165883-02
18. 1h-1,2,3-triazole-4-carboxamide, 1-((2,6-difluorophenyl)methyl)-
19. Dsstox_cid_26506
20. Dsstox_rid_81675
21. Dsstox_gsid_46506
22. 1-[(2,6-difluorophenyl)methyl]-1h-1,2,3-triazole-4 Carboxamide
23. Smr000857122
24. C10h8f2n4o
25. Cas-106308-44-5
26. Unii-wfw942pr79
27. Rufinamide [usan:inn:ban]
28. Syn111
29. Syn-111
30. Cgp33101
31. Banzel (tn)
32. Mfcd00865314
33. Rufinamide (banzel)
34. Cgp 33,101
35. Rufinamide [mi]
36. Rufinamide [inn]
37. Rufinamide [jan]
38. Rufinamide [usan]
39. Rufinamide [vandf]
40. Rufinamide [mart.]
41. Rufinamide [usp-rs]
42. Rufinamide [who-dd]
43. Rufinamide (jan/usp/inn)
44. Mls001332513
45. Mls001332514
46. Rufinamide [ema Epar]
47. Schembl230448
48. Gtpl7470
49. Zinc7782
50. Chembl1201754
51. Dtxsid1046506
52. Rufinamide [orange Book]
53. Chebi:134966
54. Hms2232m19
55. Hms3262o14
56. Hms3371a06
57. Hms3651o05
58. Hms3884g07
59. Rufinamide [usp Monograph]
60. Bcp21828
61. Hy-a0042
62. Tox21 112267
63. Tox21_112267
64. Tox21_500796
65. Bdbm50515492
66. S1256
67. Akos005145897
68. Rufinamide, >=98% (hplc), Powder
69. Tox21_112267_1
70. Ac-1429
71. Ccg-222100
72. Cs-1455
73. Db06201
74. Lp00796
75. Sb18904
76. Sdccgsbi-0633757.p001
77. Ncgc00165883-01
78. Ncgc00165883-03
79. Ncgc00165883-04
80. Ncgc00165883-11
81. Ncgc00261481-01
82. As-13861
83. Ft-0656828
84. Ft-0674479
85. R0143
86. Sw219770-1
87. C71253
88. D05775
89. Ab00918347-05
90. Ab00918347_06
91. 308r445
92. A801414
93. Q408565
94. Sr-01000842156
95. J-001568
96. Sr-01000842156-4
97. 1-[(2,6-difluorophenyl)methyl]-4-triazolecarboxamide
98. F0001-2404
99. Z1541638521
100. 1-(2,6-difluorobenzyl)-1h-1,2,3-triazol-4-carboxamide
101. Rufinamide, United States Pharmacopeia (usp) Reference Standard
102. 1-[[2,6-bis(fluoranyl)phenyl]methyl]-1,2,3-triazole-4-carboxamide
| Molecular Weight | 238.19 g/mol |
|---|---|
| Molecular Formula | C10H8F2N4O |
| XLogP3 | 0.7 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Exact Mass | 238.06661722 g/mol |
| Monoisotopic Mass | 238.06661722 g/mol |
| Topological Polar Surface Area | 73.8 Ų |
| Heavy Atom Count | 17 |
| Formal Charge | 0 |
| Complexity | 282 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Banzel |
| PubMed Health | Rufinamide (By mouth) |
| Drug Classes | Anticonvulsant |
| Drug Label | BANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H... |
| Active Ingredient | Rufinamide |
| Dosage Form | Tablet; Suspension |
| Route | Oral |
| Strength | 200mg; 40mg/ml; 400mg |
| Market Status | Prescription |
| Company | Eisai |
| 2 of 2 | |
|---|---|
| Drug Name | Banzel |
| PubMed Health | Rufinamide (By mouth) |
| Drug Classes | Anticonvulsant |
| Drug Label | BANZEL (rufinamide) is a triazole derivative structurally unrelated to currently marketed antiepileptic drugs (AEDs). Rufinamide has the chemical name 1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-triazole-4 carboxamide. It has an empirical formula of C10H... |
| Active Ingredient | Rufinamide |
| Dosage Form | Tablet; Suspension |
| Route | Oral |
| Strength | 200mg; 40mg/ml; 400mg |
| Market Status | Prescription |
| Company | Eisai |
Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome.
FDA Label
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
At high concentrations will inhibit action of mGluR5 subtype receptors thus preventing the production of glutamate.
Voltage-Gated Sodium Channel Blockers
A class of drugs that inhibit the activation of VOLTAGE-GATED SODIUM CHANNELS. (See all compounds classified as Voltage-Gated Sodium Channel Blockers.)
Anticonvulsants
Drugs used to prevent SEIZURES or reduce their severity. (See all compounds classified as Anticonvulsants.)
N03AF03
N03AF03
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N03 - Antiepileptics
N03A - Antiepileptics
N03AF - Carboxamide derivatives
N03AF03 - Rufinamide
Absorption
The oral suspension and tablet are bioequivalent on a mg per mg basis. Rufinamide is well absorbed but the rate is slow and the extent of absorption decreases as dose is increases. Based on urinary excretion, the extent of absorption was at least 85% following oral administration of a single dose of 600 mg rufinamide tablet under fed conditions. Bioavailability= 70%-85% (decreases with increasing doses); Tmax, fed and fasted states= 4-6 hours; Cmax, 10 mg/kg/day= 4.01 L/mL; Cmax, 30mg/kg/day= 8.68 L/mL; AUC (0h-12h), 10mg/kg/day= 37.847 gh/mL; AUC (0h-12h), 30mg/kg/day= 89.359 gh/mL.
Route of Elimination
Renally (91%; 66% as CGP 47292, 2% as unchanged drug) and fecally (9%) eliminated.
Volume of Distribution
Rufinamide was evenly distributed between erythrocytes and plasma. The apparent volume of distribution is dependent upon dose and varies with body surface area. The apparent volume of distribution was about 50 L at 3200 mg/day. Volume of distribution is similar between adults and children and is non-linear.
Rufinamide is extensively metabolized but has no active metabolites. Metabolism by carboxyesterases into inactive metabolite CGP 47292, a carboxylic acid derivative, via hydrolysis is the primary biotransformation pathway. A few minor additional metabolites were detected in urine, which appeared to be acyl-glucuronides of CGP 47292. The cytochrome P450 enzyme system or glutathiones are not involved with the metabolism of rufinamide. Rufinamide is a weak inhibitor of CYP 2E1. Rufinamide is a weak inducer of CYP 3A4 enzymes.
Elimination half-life, healthy subjects and patients with epilepsy = 6-10 hours.
Rufinamide is a triazole derivative antiepileptic that prolongs the inactive state of voltage gated sodium channels thus stabilizing membranes, ultimately blocking the spread of partial seizure activity.
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-23
Pay. Date : 2012-11-13
DMF Number : 26316
Submission : 2012-10-09
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-07-21
Pay. Date : 2015-03-16
DMF Number : 29034
Submission : 2015-03-27
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2019-01-03
Pay. Date : 2018-07-26
DMF Number : 26385
Submission : 2012-09-29
Status : Active
Type : II
Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm :
NDC Package Code : 69766-050
Start Marketing Date : 2018-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2018-09-10
Pay. Date : 2018-07-16
DMF Number : 32713
Submission : 2018-04-30
Status : Active
Type : II
Date of Issue : 2025-07-07
Valid Till : 2028-07-14
Written Confirmation Number : WC-0021
Address of the Firm :
NDC Package Code : 14501-0058
Start Marketing Date : 2010-03-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-24
Pay. Date : 2012-11-06
DMF Number : 26209
Submission : 2012-10-23
Status : Active
Type : II
Date of Issue : 2022-07-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
NDC Package Code : 66039-881
Start Marketing Date : 2012-10-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2023-05-03
Pay. Date : 2023-04-12
DMF Number : 38182
Submission : 2023-03-23
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-02-07
Pay. Date : 2012-11-09
DMF Number : 25676
Submission : 2012-01-04
Status : Active
Type : II
NDC Package Code : 46438-0661
Start Marketing Date : 2021-04-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2021-10-07
Pay. Date : 2021-07-13
DMF Number : 36077
Submission : 2021-08-18
Status : Active
Type : II
NDC Package Code : 65977-0068
Start Marketing Date : 2008-11-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28284
Submission : 2014-05-09
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-23
Pay. Date : 2012-11-13
DMF Number : 26316
Submission : 2012-10-09
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-04-24
Pay. Date : 2012-11-06
DMF Number : 26209
Submission : 2012-10-23
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2015-07-21
Pay. Date : 2015-03-16
DMF Number : 29034
Submission : 2015-03-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-02-07
Pay. Date : 2012-11-09
DMF Number : 25676
Submission : 2012-01-04
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2021-10-07
Pay. Date : 2021-07-13
DMF Number : 36077
Submission : 2021-08-18
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2023-05-03
Pay. Date : 2023-04-12
DMF Number : 38182
Submission : 2023-03-23
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2018-09-10
Pay. Date : 2018-07-16
DMF Number : 32713
Submission : 2018-04-30
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2019-01-03
Pay. Date : 2018-07-26
DMF Number : 26385
Submission : 2012-09-29
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28284
Submission : 2014-05-09
Status : Inactive
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Date of Issue : 2022-07-06
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate Ankleshwar, Distt- Bharuch - 393002, Guja...

Date of Issue : 2025-09-24
Valid Till : 2028-08-08
Written Confirmation Number : WC-0383
Address of the Firm : Unit-ll, Sy No * Parts of 454,455,457,458 & 459 Chandampet-Village, Shankarampet...

Date of Issue : 2025-07-07
Valid Till : 2028-07-14
Written Confirmation Number : WC-0021
Address of the Firm : Sy. Nos, 317,320,321,322,323,604 & 605, Pincode-502329, Rudraram (Village), Pata...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC Package Code : 50923-0614
Start Marketing Date : 2004-01-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66039-881
Start Marketing Date : 2012-10-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 66005-0037
Start Marketing Date : 2011-01-10
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46438-0661
Start Marketing Date : 2021-04-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 46438-0662
Start Marketing Date : 2021-04-15
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 65977-0068
Start Marketing Date : 2008-11-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 69766-050
Start Marketing Date : 2018-04-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 14501-0058
Start Marketing Date : 2010-03-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Omgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.
About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...
Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.
About the Company : Lupin Manufacturing Solutions (LMS), a wholly owned Lupin subsidiary, offers high-quality APIs and end-to-end CDMO services from R&D to commercial scale. Backed by five decades of ...
About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...

About the Company : Dipharma is a leading European manufacturer of Active Pharmaceutical Ingredients that has been developing innovative and proprietary processes since 1949. We support our custome...

About the Company : Glenmark was founded with a vision to emerge as a leading integrated research-based, global pharmaceutical company. Our branded generics business has a significant presence in mark...

About the Company : Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs) in India. Indoco has a strong int...

About the Company : Micro Labs Limited is a diversified healthcare company with cutting-edge R&D, advanced manufacturing facilities, and a strong distribution network. It ranks among India's top pharm...

About the Company : Vasista Group, which includes Vasista Life Sciences Pvt Ltd. and Vasista Pharma Chem Pvt Ltd., we aim to be a leading player in the global healthcare industry. Since our inception,...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Quizartinib,Rufinamide
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Quizartinib,Rufinamide
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quizartinib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 18, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Inovelon (rufinamide) is triazole derivative,believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in brain involved in overexcitement of neurons that potentially causes seizures, so as to prolong their inactive state.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Inovelon
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eisai Satisfies All-case Study Requirement For Antiepileptic Agent Inovelon®
Details : Inovelon (rufinamide) is triazole derivative,believed to exert its antiepileptic effects by regulating activity of voltage-gated sodium channels in brain involved in overexcitement of neurons that potentially causes seizures, so as to prolong their inact...
Product Name : Inovelon
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 03, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays).
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Rufinamide-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives US FDA Approval for Rufinamide Tablets
Details : Rufinamide is used with other medication(s) to control seizures in people who have Lennox-Gastaut syndrome (a severe form of epilepsy that begins during childhood and causes several types of seizures, behavioral disturbances, and developmental delays).
Product Name : Rufinamide-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 18, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Neurology Brand Name: Rufinamide-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval for Rufinamide Oral Suspension
Details : Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Product Name : Rufinamide-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 22, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lennox Gastaut Syndrome.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 19, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 29, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 29, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 28, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Long Term Extension Study of E2080 in Lennox-Gastaut Patients
Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Lead Product(s): Rufinamide,Inapplicable
Therapeutic Area: Rare Diseases and Disorders Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 22, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rufinamide,Inapplicable
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rufinamide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Lennox Gastaut Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 22, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 530-78-9
End Use API : Rufinamide
About The Company : Established in 2000, Shodhana Laboratories offers a wide range of APIs and intermediates and caters to the generic and custom requirements of some of the most p...

ETHYL 3-(DIMETHYLAMINO)ACRYLATE
CAS Number : 924-99-2
End Use API : Rufinamide
About The Company : Vasista Group, which includes Vasista Life Sciences Pvt Ltd. and Vasista Pharma Chem Pvt Ltd., we aim to be a leading player in the global healthcare industry. ...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 16/01/2007
Application Number : 20050406000047
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 400mg
Packaging :
Approval Date : 16/01/2007
Application Number : 20050406000054
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Inovelon
Dosage Form : Oral Suspension
Dosage Strength : 40MG
Packaging :
Approval Date : 2012-03-20
Application Number : 06378017
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 100MG
Packaging :
Approval Date : 2007-07-31
Application Number : 06378001
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 400MG
Packaging :
Approval Date : 2007-07-31
Application Number : 06378015
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Italy
Brand Name : Inovelon
Dosage Form : Rufinamide 200Mg 60 Units Oral Use
Dosage Strength : 60 cpr riv 200 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Norway
Brand Name : Inovelon
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 100 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info :
Registration Country : Norway
Brand Name : Inovelon
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 200 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 200mg
Packaging :
Approval Date : 06/01/2009
Application Number : 58097
Regulatory Info : Allowed
Registration Country : Switzerland

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Inovelon
Dosage Form : Film Coated Tablet
Dosage Strength : 400mg
Packaging :
Approval Date : 06/01/2009
Application Number : 58097
Regulatory Info : Allowed
Registration Country : Switzerland

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Tablet
Grade : Oral
Application : Controlled & Modified Release
Excipient Details : ACTILLETS are microcrystalline cellulose spheres developed using advanced drug delivery technology to enable effective loading & coating of particles.
Pharmacopoeia Ref : NA
Technical Specs : Not Available
Ingredient(s) : Microcrystalline Cellulose Excipients
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : CS90 is a directly compressible calcium carbonate with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-175 µm, Tapped Density: 0.85
Ingredient(s) : Calcium Carbonate Excipient
Dosage Form : Tablet
Grade : Oral
Application : Direct Compression
Excipient Details : DC SIM 100 is a directly compressible simethicone powder used for antacid and anti-gas tablets.
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : MS90 is a directly compressible magnesium hydroxide with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-170 µm, Tapped Density: 0.80
Ingredient(s) : Magnesium Hydroxide Excipient
Dosage Form : Softgels
Grade : Oral
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Dosage Form : Gel
Grade : Parenteral, Topical
Brand Name : Polyethylene Glycol 200 N...
Application : Topical
Excipient Details : A & C's Polyethylene Glycol 200 is an excipient which meets the NF monograph.
Pharmacopoeia Ref : NF
Technical Specs : Polyethylene Glycol 200; Polyethylene Glycol 300; Polyethylene Glycol 400; Low Endotoxin
Ingredient(s) : Polyethylene Glycol Excipient
Excipients Web Link
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Parenteral
Brand Name : Polyethylene Glycol 300 N...
Application : Topical
Excipient Details : A & C's Polyethylene Glycol 300 is an excipient which meets the NF monograph.
Pharmacopoeia Ref : NF
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol Excipient
Excipients Web Link
Dosage Form : Gel
Grade : Topical, Parenteral
Brand Name : Polyethylene Glycol 400
Application : Topical
Excipient Details : A&C's Polyethylene Glycol 400 USP-NF is a short chain non-ionic surfactant.
Pharmacopoeia Ref : Not Available
Technical Specs : Low Endotoxin
Ingredient(s) : Polyethylene Glycol Excipient
Excipients Web Link
Dosage Form : Tablet
Grade : Topical and Oral
Brand Name : Polyethylene Glycol 400
Application : Controlled & Modified Release
Pharmacopoeia Ref : Not Available
Technical Specs : Not Available
Ingredient(s) : Polyethylene Glycol Excipient
Excipients Web Link
Dosage Form : Cream / Lotion / Ointment
Grade : Topical and Oral
Application : Topical
Excipients Web Link
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Global Sales Information
Market Place
Reply
23 Dec 2020

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ANALYTICAL
ABOUT THIS PAGE
92
PharmaCompass offers a list of Rufinamide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rufinamide manufacturer or Rufinamide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rufinamide manufacturer or Rufinamide supplier.
PharmaCompass also assists you with knowing the Rufinamide API Price utilized in the formulation of products. Rufinamide API Price is not always fixed or binding as the Rufinamide Price is obtained through a variety of data sources. The Rufinamide Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Banzel manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Banzel, including repackagers and relabelers. The FDA regulates Banzel manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Banzel API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Banzel manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Banzel supplier is an individual or a company that provides Banzel active pharmaceutical ingredient (API) or Banzel finished formulations upon request. The Banzel suppliers may include Banzel API manufacturers, exporters, distributors and traders.
click here to find a list of Banzel suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Banzel DMF (Drug Master File) is a document detailing the whole manufacturing process of Banzel active pharmaceutical ingredient (API) in detail. Different forms of Banzel DMFs exist exist since differing nations have different regulations, such as Banzel USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Banzel DMF submitted to regulatory agencies in the US is known as a USDMF. Banzel USDMF includes data on Banzel's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Banzel USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Banzel suppliers with USDMF on PharmaCompass.
A Banzel written confirmation (Banzel WC) is an official document issued by a regulatory agency to a Banzel manufacturer, verifying that the manufacturing facility of a Banzel active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Banzel APIs or Banzel finished pharmaceutical products to another nation, regulatory agencies frequently require a Banzel WC (written confirmation) as part of the regulatory process.
click here to find a list of Banzel suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Banzel as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Banzel API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Banzel as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Banzel and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Banzel NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Banzel suppliers with NDC on PharmaCompass.
Banzel Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Banzel GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Banzel GMP manufacturer or Banzel GMP API supplier for your needs.
A Banzel CoA (Certificate of Analysis) is a formal document that attests to Banzel's compliance with Banzel specifications and serves as a tool for batch-level quality control.
Banzel CoA mostly includes findings from lab analyses of a specific batch. For each Banzel CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Banzel may be tested according to a variety of international standards, such as European Pharmacopoeia (Banzel EP), Banzel JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Banzel USP).